The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumRecap - We ended the week with some commentary based largely on the strength observed in recent biotech stocks immediately following financings. It’s the momentum behind recent secondary offerings  – … Continue Reading
Read nowInsights - Synageva BioPharma Corp (GEVA) announced the pricing of its secondary offering after the bell on Wednesday. The company priced 2.0 million shares, or 2.3 million including the … Continue Reading
PremiumResearch - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
PremiumInsights - Sarepta Therapeutics (SRPT) last Thursday morning released its fourth quarter and full-year 2013 financial results and hosted a conference call for investors. SRPT’s 2014 outlook … Continue Reading
Read nowRecap - Sarepta Therapeutics (SRPT)Â on Thursday morning released its fourth quarter and full-year 2013 financial results. The company continues to await guidance from the FDA on the … Continue Reading
Read nowInsights - QLT Inc (QLTI) reported positive retreatment data on Thursday for its synthetic oral retinoid compound QLT091001 (-001), indicated for the orphan designated Leber Congenital Amaurosis … Continue Reading
Read nowInsights - Our timing couldn't have been much worse this week, though our thesis is intact on this nutraceutical business.
Premium
